Phosphorylcholine PC-mAb Effects in Subjects With Elevated Lipoprotein a
Status:
Terminated
Trial end date:
2018-07-03
Target enrollment:
Participant gender:
Summary
Inflammation and abnormal amount of lipids in the blood are key factors for the development
and progression of atherosclerosis (thickening of the artery wall) and cardiovascular
disease. Lipoprotein (a) is a pro-inflammatory plasma lipoprotein that is believed to be a
risk factor for cardiovascular diseases. Vascular inflammation generates a range of effects,
including endothelial dysfunction and migration of white blood cells into the vessel wall,
which results in increased risk of cardiovascular events.
This study is designed to assess the effects of multiple monthly intravenous infusions with
the fully human antibody called PC-mAb, in subjects with elevated lipoprotein (a).